Evidence map›Paper›PMID 41165174›Full record

ArticleACS chemical neuroscience2025

Mass Spectrometry-Based Comparative Analysis of

Lingbo Zhao, Chunyan Hou, Yu Gao, Hong Jin, Chun-Feng Liu, Shuwei Li, Junfeng Ma, Shuang Yang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lingbo ZhaoCenter for Clinical Mass Spectrometry, School of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
Chunyan HouDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown UniversityMedical Center, Georgetown University, Washington, District of Columbia 20057, United States.ORCID 0000-0001-5966-1899
Yu GaoCenter for Clinical Mass Spectrometry, School of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
Hong JinDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Chun-Feng LiuDepartment of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.ORCID 0000-0002-8364-0219
Shuwei LiNanjing Apollomics Biotech, Inc., Nanjing, Jiangsu 210033, China.
Junfeng MaDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown UniversityMedical Center, Georgetown University, Washington, District of Columbia 20057, United States.ORCID 0000-0002-5183-5425
Shuang YangCenter for Clinical Mass Spectrometry, School of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.ORCID 0000-0001-7958-0594

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder lacking definitive diagnostic tests. To identify new diagnostic biomarkers, we employed glycoproteomics-mass spectrometry (MS) to investigate dynamic changes in protein

Indexed as

Body FluidsGlycoproteinsParkinson DiseaseAgedBiomarkersClusterinFemaleGlycosylationHumansMaleMass SpectrometryMiddle AgedProteomicsSalivaBiomarkersClusterinGlycoproteinsglycosylationmass spectrometryParkinson’s diseasesalivaserumurine

Identifiers

PMID41165174
PMCPMC12636009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.